Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Yuliya Pylayeva-Gupta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4458-9091; OpenAlex author ID A5063378046; NIH RePORTER profile ID 9707697. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 7)
Trials
0
Grants
3
Labs led
1
Collaborators
16
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 4 papers · 2021: 1 paper · 2022: 1 paper, 1 grant · 2023: none · 2024: none · 2025: 1 grant · 2026: 1 paper, 1 grant

Papers 9

  1. Dynamic regulation of hypoxia-associated regulatory CD39+CD73+ and IL35+ B cells in pancreatic cancer. Last author DOI 10.3389/fimmu.2026.1814123↗
  2. Low-Intensity Focused Ultrasound Produces Immune Response in Pancreatic Cancer. Last author DOI 10.1016/j.ultrasmedbio.2022.06.017↗
  3. B Cell Receptor Signaling and Protein Kinase D2 Support Regulatory B Cell Function in Pancreatic Cancer. Last author DOI 10.3389/fimmu.2021.745873↗
  4. Pancreatic cancer-associated inflammation drives dynamic regulation of p35 and Ebi3. Last author DOI 10.1016/j.cyto.2019.154817↗
  5. Rab27a plays a dual role in metastatic propensity of pancreatic cancer. Last author DOI 10.1038/s41598-020-64248-1↗
  6. Pancreatic Cancer Thrives on Hijacking a Homeostatic Tissue Repair Pathway. Co-author DOI 10.1053/j.gastro.2020.02.010↗
  7. B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-19-0349↗
  8. IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-17-0710↗
  9. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. First author DOI 10.3390/cancers8040045↗

Grants 3

  1. Divergent Roles of MerTK,Tyro3, and Axl in Pancreatic Cancer and Metastasis R01CA270792↗
  2. Function of IL35+ B cells in pancreatic cancer R37CA230786↗
  3. Parametric optimization of ultrasound-mediated immuno-modulation for pancreatic cancer therapy R21CA246550↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. H. Shelton Earp · 1 shared grant, 2026 · strength 1.26
  2. Nancy Porterfield Kren · 4 shared papers, 2020–2026 · strength 0.85
  3. Paul A Dayton · 1 shared paper, 1 shared grant, 2022 · strength 0.84
  4. Daniel E. Michaud · 5 shared papers, 2018–2021 · strength 0.65
  5. Bhalchandra Mirlekar · 4 shared papers, 2018–2021 · strength 0.50
  6. Hannah R. Hall · 1 shared paper, 2026 · strength 0.43
  7. Autumn J. McRee · 2 shared papers, 2020–2022 · strength 0.28
  8. Jordan B. Joiner · 1 shared paper, 2022 · strength 0.19
  9. William G. Hawkins · 1 shared paper, 2020 · strength 0.09
  10. Naim U. Rashid · 1 shared paper, 2020 · strength 0.09
  11. Jen Jen Yeh · 1 shared paper, 2020 · strength 0.09
  12. Ryan C Fields · 1 shared paper, 2020 · strength 0.09
  13. David G DeNardo · 1 shared paper, 2020 · strength 0.09
  14. Daniel Zeitouni · 1 shared paper, 2016 · strength 0.08
  15. Kirsten L. Bryant · 1 shared paper, 2016 · strength 0.08
  16. Channing J. Der · 1 shared paper, 2016 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.